The investigation of hydroxychloroquine usage in patients with rheumatoid arthritis in China
张萨丽,王秀茹,李春,安媛,周云杉,刘婧,李小峰,王莉枝,王彩虹
DOI: https://doi.org/10.3760/cma.j.issn.1007-7480.2013.09.003
2013-01-01
Abstract:Objective To investigate the clinical usage of hydroxychloroquine (HCQ) in patients with rheumatoid arthritis (RA).Methods Data were obtained from 858 RA patients,who were randomly selected from Department of Rheumatology in 20 university hospitals in China.Data on social status,clinical conditions,strategy of combination therapy,and adverse events were collected.All analysis were performed using SPSS version 20.0.Demographic data was presented by descriptive analysis.Mann-Whitney U-test was used for categorical data analysis.Chi-square was used to assess the differences between the groups.Results Among 858 RA patients enrolled in the study,19.5%(167/858) had received HCQtherapy,the majority 64.7% (108/167) of the patients were administered continued HCQ treatment for at least 3 months,77.8%(130/167)were administered the recommended dose of 6.5 mg ·kg-1 ·d-1 and 94.6% (158/167) of the patients were administered HCQ combined with methotrexate (MTX) or leflunomide (LEF).Only 9 patients received HCQ monotherapy.Adequate duration of HCQ was benefits to RA patients in the duration of morning stiffness (U=1 670.5,P<0.05),tender joint counts (U=1 380.5,P<0.01) and swollen joint counts (U=67 974.5,P<0.01),VAS pain score (U=2 086.0,P=0.01),patient rating VAS(U=2 181.5,P<0.05),physician rating VAS (U=2 086.5,P<0.05),DAS28 score (U=827.5,P<0.01),HAQ score (U=1 855.5,P<0.01) and ESR (U=1 231.0,P<0.05).The incidence of adverse events of HCQ was 5.4% (9/167).Ocular toxicity (such as maculopathy,photopsia and intraocular foreign body sensation) and allergy were the main side effects with the incidence of 1.8%(3/167) and 1.2%(2/167),respectively.Conclusion 19.5% of RA patients in China have received HCQ treatment,94.6% of whom have received combination therapy.Patients who have been treated for the recommended duration of HCQ are greatly improved in disease.activity and maintenance of joint function.The incidence of adverse events in HCQ therapy is low,which is 5.4% among patients with RA in China.